# Drug-drug Interaction Study: Influence of Vilaprisan on Pharmacodynamics (PD) and Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)

> **NCT03210246** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 71 (actual)

## Conditions studied

- Clinical Trial ,Phase I

## Interventions

- **DRUG:** Vilaprisan (BAY 1002670)
- **DRUG:** Vilaprisan Placebo
- **DRUG:** Microgynon
- **DRUG:** Microgynon Placebo

## Key facts

- **NCT ID:** NCT03210246
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-17
- **Primary completion:** 2018-06-21
- **Final completion:** 2019-01-23
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2019-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03210246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03210246, "Drug-drug Interaction Study: Influence of Vilaprisan on Pharmacodynamics (PD) and Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03210246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*